ArticleScientific reports2025
Neoadjuvant chemotherapy is not necessarily applicable to patients with LN1-3 positive Luminal-B type operable breast cancer.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The purpose of is to identify the necessity of neoadjuvant chemotherapy in luminal type breast cancer patients (HR-positive HER2-negative) by exploring the treatment characteristics, treatment plan, surgical choice and long-term prognosis between neoadjuvant chemotherapy and adjuvant chemotherapy. A retrospective review of all patients undergoing neoadjuvant chemotherapy at the Fourth Hospital of Hebei Medical University, China, between January 2014 and December 2018 was conducted. These were matched 1:2 by Propensity score matching method (PSM) to patients undergoing adjuvant chemotherapy. Matching variables were common tumor characteristics. Ninety-seven patients received neoadjuvant chemotherapy and 651 patients received adjuvant chemotherapy. After PSM, 79 patients in neoadjuvant chemotherapy group (study group) and 145 patients in adjuvant chemotherapy (control group) were included in the study. Median follow-up was 75 and 60 months for the patients before and after PSM, respectively. The estimated 5-year disease-free survival was 76.4% and 81.1% (P = 0.0208), 5-year overall survival was 77.9% and 88.6% (P = 0.0261) between the neoadjuvant chemotherapy group and adjuvant chemotherapy before PSM. Patients in the adjuvant treatment group had better prognosis. After PSM, the estimated 5-year disease-free survival was 79.4% and 78.3% (P = 0.770), 5-year overall survival was 88.7% and 87.7% (P = 0.400) between the neoadjuvant chemotherapy group and adjuvant chemotherapy. The 7-year update follow up DFS and OS also have no differ significantly between the two groups. It may be reasonable to forego neoadjuvant chemotherapy and prioritize surgical intervention for patients with cN1, high PR expression, Luminal B(HR+/HER2-) breast cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.